Dr. Awan Discusses Challenges With Ibrutinib in CLL
In Partnership With:
Farrukh Awan, MBBS, associate professor, The Ohio State University Comprehensive Cancer Center, discusses challenges with ibrutinib (Imbruvica) in chronic lymphocytic leukemia.
Farrukh Awan, MBBS, associate professor, The Ohio State University Comprehensive Cancer Center, discusses challenges with ibrutinib (Imbruvica) in chronic lymphocytic leukemia (CLL).
The key issues with usage of ibrutinib in patients with CLL are duration and the management of side effects.
Current ongoing trials are tackling these challenges, says Awan, results of which will hopefully bring more knowledge to the field.
Related Videos
Related Content
